Two doses of an experimental H5N8 avian influenza vaccine raised antibodies in most of the adults who received them, including people aged 65 and older, according to a phase 2 trial published online on 7 November 2026. The paper in Vaccine reports blood-test results. The published abstract does not report whether anyone was protected from infection.
The vaccine is an MF59-adjuvanted, cell-based shot built on A/Astrakhan/3212/2020, a clade 2.3.4.4b H5N8 virus. An adjuvant is an added ingredient meant to strengthen the immune response. Cell-based means the antigen was grown in cultured cells rather than in chicken eggs. The trial was randomized, observer-blind and multi-center. The abstract gives results for 239 vaccinated adults: 121 aged 18 to 64, a group that included poultry workers, and 118 aged 65 or older. Each of them received two priming doses. The abstract does not list every clinic. The first author, Adam Brosz, is affiliated with Velocity Research in Grand Island, Nebraska. The other authors work for CSL Seqirus in Amsterdam, Waltham, Massachusetts, and Melbourne. The PubMed record says Brosz received financial support from CSL Seqirus and that the company authors are employees who hold equity or stock. The paper's copyright line names CSL Seqirus.
What the blood tests showed
On day 43, three weeks after the second dose, hemagglutination-inhibition antibodies had risen 13.7-fold in the younger group and 10.2-fold in the older group. Seroconversion, a defined jump in antibody level, reached 75.8 percent of the 18-to-64 group (95 percent confidence interval 66.1 to 83.8) and 71.0 percent of the older group (61.1 to 79.6). A titer of at least 1:40, a threshold long used for seasonal flu vaccines, was reached by 75.8 percent and 73.0 percent (63.2 to 81.4).
A second assay, microneutralization, was run on a subset. Seroconversion there was 80.6 percent (68.6 to 89.6) in the younger cohort and 70.0 percent (56.8 to 81.2) in the older one. Titers of at least 1:40 were more common on that test: 83.9 percent (72.3 to 92.0) and 86.7 percent (75.4 to 94.1). The abstract says the immune responses did not differ notably by whether participants worked with poultry.
Most solicited side effects were mild or moderate and cleared within three days. Unsolicited adverse events were reported by 16.7 percent of participants by day 43. The abstract does not give a count of serious adverse events.
The journal accepted the paper on 19 October 2026, after receiving it on 28 August and a revision on 15 October. Online publication followed on 7 November.
What an antibody study can support
About one in four younger adults, and a larger share of the older group, did not seroconvert on the hemagglutination-inhibition test. The average rise was smaller in adults 65 and older than in younger adults. A 1:40 titer is a laboratory benchmark borrowed from seasonal flu vaccines. For a new H5 strain, that number is a proxy, and the abstract does not show that people who reached it avoided illness.
The authors conclude that the data support use of this vaccine as a public-health tool against H5 influenza. That sentence is their reading of an immunogenicity study sponsored and co-written by the manufacturer. Antibody results from 239 vaccinated adults are a measured step in testing a pandemic candidate. Whether the vaccine prevents disease, and whether it should be used routinely, are questions this abstract leaves open.